Concordia Settles U.S. Antitrust Claims Over Drug Pact With ParDavid McLaughlin
Concordia Healthcare Corp. and Par Pharmaceutical Holdings Inc. agreed to settle U.S. claims that the companies engaged in anticompetitive conduct by agreeing not to compete in the sale of a generic prescription drug.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.